Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer.


Journal

Cancer research and treatment
ISSN: 2005-9256
Titre abrégé: Cancer Res Treat
Pays: Korea (South)
ID NLM: 101155137

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 18 04 2020
accepted: 20 08 2020
pubmed: 29 8 2020
medline: 31 8 2021
entrez: 29 8 2020
Statut: ppublish

Résumé

Systemic inflammatory response is a critical factor that promotes the initiation and metastasis of malignancies including pancreatic cancer (PC). This study was designed to determine and compare the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and fibrinogen-to-albumin ratio (FAR) in resectable PC and locally advanced or metastatic PC. Three hundred fifty-three patients with resectable PC and 807 patients with locally advan-ced or metastatic PC were recruited in this study. These patients were classified into a training set (n=758) and a validation set (n=402). Kaplan-Meier survival plots and Cox proportional hazards regression models were used to analyze prognosis. Overall survival (OS) was significantly better for patients with resectable PC with low preoperative PLR (p=0.048) and MLR (p=0.027). Low FAR, MLR, NLR (p < 0.001), and PLR (p=0.003) were significantly associated with decreased risk of death for locally advanced or metastatic PC patients. FAR (hazard ratio [HR], 1.522; 95% confidential interval [CI], 1.261 to 1.837; p < 0.001) and MLR (HR, 1.248; 95% CI, 1.017 to 1.532; p=0.034) were independent prognostic factors for locally advanced or metastatic PC. The prognostic roles of FAR, MLR, NLR, and PLR in resectable PC and locally advanced or metastatic PC were different. FAR showed the most prognostic power in locally advanced or metastatic PC. Low FAR was positively correlated with OS in locally advanced or metastatic PC, which could be used to predict the prognosis.

Identifiants

pubmed: 32854494
pii: crt.2020.330
doi: 10.4143/crt.2020.330
pmc: PMC7811998
doi:

Substances chimiques

Albumins 0
Biomarkers, Tumor 0
Fibrinogen 9001-32-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-139

Subventions

Organisme : National Natural Science Foundation of China
ID : 81672428
Organisme : National Natural Science Foundation of China
ID : 81872427, 81773210
Organisme : Applied Technology Research and Development Plan of Heilongjiang Province
ID : GA19C002
Organisme : Wujieping Science Foundation of China
ID : 320.6750.15253
Organisme : Haiyan Research Fund
ID : JJLX2016-01
Organisme : Haiyan Research Fund
ID : JJQN2019-07
Organisme : Haiyan Research Fund
ID : JJZD2020-03
Organisme : Beijing CSCO Clinical Oncology Research
ID : Y-MX2016-021
Organisme : Beijing CSCO Clinical Oncology Research
ID : Y-HS2017-033
Organisme : Heilongjiang postdoctoral fund
ID : LBH-Z18140

Références

J Cancer Res Clin Oncol. 2017 Dec;143(12):2413-2424
pubmed: 28801734
Cancer. 2015 Feb 15;121(4):545-55
pubmed: 25336438
ACS Appl Mater Interfaces. 2019 Mar 6;11(9):9333-9342
pubmed: 30758933
Pancreatology. 2015 Mar-Apr;15(2):145-50
pubmed: 25641673
BMC Cancer. 2018 Oct 3;18(1):942
pubmed: 30285656
Clin Chem Lab Med. 2015 Feb;53(3):499-506
pubmed: 25389993
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gynecol Oncol. 2015 Sep;138(3):560-5
pubmed: 26163893
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Cancer Treat Rev. 2015 Dec;41(10):960-70
pubmed: 26604093
J Infect Dis. 2015 Jul 15;212 Suppl 1:S67-73
pubmed: 26116736
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Circulation. 2012 Dec 4;126(23):2739-48
pubmed: 23129601
Cancers (Basel). 2019 Jun 24;11(6):
pubmed: 31238514
Br J Cancer. 2015 Feb 3;112(3):461-7
pubmed: 25584490
Pharmacol Ther. 2019 Sep;201:202-213
pubmed: 31158393
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Pancreas. 2015 Aug;44(6):977-82
pubmed: 25931258
BMC Cancer. 2014 Aug 05;14:566
pubmed: 25096189
J Cancer. 2017 Apr 8;8(6):1025-1029
pubmed: 28529615
J Surg Oncol. 2013 Jan;107(1):97-103
pubmed: 22991309
Hematol Oncol. 2016 Dec;34(4):184-192
pubmed: 26052918
Future Oncol. 2018 Feb;14(3):229-239
pubmed: 29338337
Cancer Res Treat. 2019 Apr;51(2):664-671
pubmed: 30064197
Gut. 2019 Jun;68(6):960-968
pubmed: 30121626
Ann Surg Oncol. 2017 Mar;24(3):808-815
pubmed: 27770341
Cancer Treat Rev. 2017 Jul;58:1-13
pubmed: 28602879
Ann N Y Acad Sci. 2001;936:406-25
pubmed: 11460495
Hepatology. 1988 Mar-Apr;8(2):385-401
pubmed: 3281888
Cancer Med. 2018 Apr;7(4):1221-1231
pubmed: 29533009

Auteurs

Lin Fang (L)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Fei-Hu Yan (FH)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Chao Liu (C)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Jing Chen (J)

Department of Hematopathology, Anshan Hospital, The First Affiliated Hospital of China Medical University, Anshan, China.

Dan Wang (D)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Chun-Hui Zhang (CH)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Chang-Jie Lou (CJ)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Jie Lian (J)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Yang Yao (Y)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Bo-Jun Wang (BJ)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Rui-Yang Li (RY)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Shu-Ling Han (SL)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Yi-Bing Bai (YB)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Jia-Ni Yang (JN)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Zhi-Wei Li (ZW)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Yan-Qiao Zhang (YQ)

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH